Juehui Liu

发表

Transcriptional Repression of Protein Kinase Cα via Sp1 by Wild Type p53 Is Involved in Inhibition of Multidrug Resistance 1 P-Glycoprotein Phosphorylation*

Dihua Yu, R. Pollock, Maocheng Zhan, 2005, Journal of Biological Chemistry.

Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance.

D. Hicklin, Dihua Yu, R. Pollock, 2006, Cancer research.

MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling.

C. Creighton, Matthew L. Anderson, A. Lazar, 2012, Cancer Research.

Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer

R. Katz, J. Kagan, Juehui Liu, 1998, Oncogene.

CARPs Are Ubiquitin Ligases That Promote MDM2-independent p53 and Phospho-p53ser20 Degradation*

W. El-Deiry, D. Dicker, E. McDonald, 2007, Journal of Biological Chemistry.

Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.

A. Lazar, J. Slopis, D. McConkey, 2011, Cancer research.

Wild-type p53 Inhibits Nuclear Factor-κB–Induced Matrix Metalloproteinase-9 Promoter Activation: Implications for Soft Tissue Sarcoma Growth and Metastasis

Dihua Yu, R. Pollock, P. Das, 2006, Molecular Cancer Research.

Epigenetic shielding: 5-hydroxymethylcytosine and 5-carboxylcytosine modulate UV induction of DNA photoproducts

Juehui Liu, 2014 .

Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma

Quan-sheng Zhu, R. Pollock, D. McConkey, 2009, Clinical Cancer Research.

Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors

Jun Liu, A. Lazar, Quan-sheng Zhu, 2011, Clinical Cancer Research.

Human Cancer Biology Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors

Jun Liu, A. Lazar, Quan-sheng Zhu, 2011 .

Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma

A. Lazar, Quan-sheng Zhu, D. Lev, 2011, Clinical Cancer Research.

Inactivation of MMAC1 in bladder transitional‐cell carcinoma cell lines and specimens

P. Steck, J. Kagan, J. Liu, 2000, Molecular carcinogenesis.

AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas

A. Lazar, R. Pollock, D. Lev, 2015, BMC Cancer.

Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation

Dihua Yu, A. Lazar, Quan-sheng Zhu, 2007, Molecular Cancer Therapeutics.

MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling.

Dina Lev, Chad J Creighton, C. Creighton, 2012, Cancer research.

Bioluminescent imaging of TRAIL-induced apoptosis through detection of caspase activation following cleavage of DEVD-aminoluciferin

W. El-Deiry, D. Dicker, Wenge Wang, 2005, Cancer biology & therapy.

Noninvasive fluorescence imaging of cell death in fresh human colon epithelia treated with 5-fluorouracil, CPT-11 and/or TRAIL

E. Furth, W. El-Deiry, Seok-Hyun Kim, 2005, Cancer biology & therapy.

Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis.

Dihua Yu, R. Pollock, P. Das, 2006, Molecular cancer research : MCR.

MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling.

C. Creighton, Matthew L. Anderson, A. Lazar, 2012, Cancer research.

Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma

R. Pollock, D. Lev, D. Yu, 2007, Gene Therapy.